Evidence map›Paper›PMID 42137288›Full record

ArticleMolecular therapy. Advances2026

A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL.

Claire Roddie, Juliana Dias, Gordon Weng-Kit Cheung, Maeve A O'Reilly, Mahnaz Abbasian, Amaia Cadinanos-Garai, Ketki Vispute, Leticia Bosshard-Carter, Marina Mitsikakou, Vedika Mehra and 14 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02431988 (COBALT), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02431988 phase1completednot on this map

COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

TypeinterventionalSponsorUniversity College, LondonRan2016 to 2022Enrolled10ConditionsDiffuse Large B-Cell LymphomaArmsLeukapheresis, Cyclophosphamide, Fludarabine, CAR19 T-Cells
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Claire RoddieCancer Institute, University College London, London, UK.
Juliana DiasCancer Institute, University College London, London, UK.
Gordon Weng-Kit CheungCancer Institute, University College London, London, UK.
Maeve A O'ReillyDepartment of Haematology, University College London Hospitals, London, UK.
Mahnaz AbbasianCancer Institute, University College London, London, UK.
Amaia Cadinanos-GaraiCancer Institute, University College London, London, UK.
Ketki VisputeCancer Institute, University College London, London, UK.
Leticia Bosshard-CarterCancer Institute, University College London, London, UK.
Marina MitsikakouCancer Institute, University College London, London, UK.
Vedika MehraCancer Institute, University College London, London, UK.
Harriet RoddyCancer Institute, University College London, London, UK.
John A HartleyCancer Institute, University College London, London, UK.
Nasir G MahmoudCancer Institute, University College London, London, UK.
Leah EnsellCancer Institute, University College London, London, UK.
Yashma PatelCancer Institute, University College London, London, UK.
Maria A V MarzoliniDepartment of Haematology, University College London Hospitals, London, UK.
Farzin FarzanehGene Vector Laboratory, Kings College London, London, UK.
Nourredine HimoudiUCL Institute of Child Health (ICH), London, UK.
Farhatullah SyedUCL Institute of Child Health (ICH), London, UK.
Bilyana PopovaCRUK UCL Cancer Trials Centre, London, UK.
Andre LopesCRUK UCL Cancer Trials Centre, London, UK.
Alexander DayCRUK UCL Cancer Trials Centre, London, UK.
Mark W LowdellCancer Institute, University College London, London, UK.
Karl S PeggsCancer Institute, University College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As demand for CAR T products increases, finding solutions to manufacturing bottlenecks becomes critical. While most current FDA-approved CAR T products are manufactured using traditional bag-based manufacturing methods, semi-automated manufacturing platforms can simplify and expedite autologous CAR T product delivery to patients. We performed the phase I COBALT study (NCT02431988) of 2

Indexed as

automationCAR T-cellslymphomamanufacture

Identifiers

PMID42137288
PMCPMC13148904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.